Contineum Therapeutics Inc. (CTNM) stock plunged Monday following mixed Phase 3 trial results for Bristol Myers Squibb & Co.'s (BMY) competing lung disease drug, admilparant.

Bristol Myers Squibb reported topline efficacy and safety results from its ALOFT-IPF trial, which evaluated admilparant, an oral LPA1 inhibitor, in patients with idiopathic pulmonary fibrosis (IPF), a progressive lung disease.

The 60 mg twice-daily dose significantly slowed the decline in lung function, measured by forced vital capacity, over 52 weeks compared with a placebo.

However, the higher 120 mg dose also slowed lung function decline but failed to reach statistical significance, raising questions about the drug's dose-response profile.

Analyst Perspectives And Implications For Contineum's Lead Asset

William Blair on Monday wrote that the data validates the observations from the Phase 2 study of admilparant at the same dose and provides encouraging results for other players developing LPAR1 antagonists, particularly Contineum, whose LPAR1 antagonist PIPE-791 (its lead asset) is in the Phase 2 PROPEL-IPF study in IPF patients.

In the first quarter of 2026, Contineum initiated the PROPEL-IPF Phase 2 trial of PIPE-791 for IPF in approximately 324 IPF patients. The primary efficacy endpoint is the change from baseline through week 26 in absolute forced vital capacity (FVC mL).

Analyst Myles Minter writes that the 120 mg dose missing statistical significance raises questions over dose-response without seeing full data.

Efficacy was described as clinically meaningful based on the totality of data; this includes several measures beyond just FVC decline, which investors were primarily focused on.

Admilparant appeared well-tolerated, which William Blair views as de-risking for hypotensive events and hepatotoxicity.

Discovery And Preclinical Characterization Of PIPE-791

In June, Contineum Therapeutics announced the publication of a manuscript describing the discovery and characterization of PIPE-791 in the Journal of Medicinal Chemistry.

Extensive structure-activity relationship studies led to the identification of a unique scaffold that was responsible for slow but tight binding to LPAR1.

Further optimizations that focused on improving brain penetration and ADME (absorption, distribution, metabolism, excretion) properties afforded PIPE-791, the first LPAR1 antagonist that could effectively traverse the blood-brain barrier and fully occupy the target receptor, with a low, once-daily oral dose.

The potential of PIPE-791 to treat both central nervous system and peripherally restricted disorders associated with aberrant LPA-LPAR1 signaling was also demonstrated in multiple preclinical disease models.

CTNM Price Action: Contineum Therapeutics shares were down 29.30% at $9.46 at the time of publication on Monday, according to market data.